Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.60 |
| ▸ | TGM2 | P21980 | 1/20 | 0.58 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.54 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.54 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.53 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 1/20 | 0.52 |
| ▸ | HINT1 | P49773 | 1/20 | 0.51 |
| ▸ | KRAS | P01116 | 2/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20442307 | 1.00 | POLB (0.61) | POLBNT5ETGM2IMPDH2TAS1R3 | |
| Deoxy Adenosinediphosphate SCHEMBL5827749 | 0.93 | TGM2 (0.63) | POLBNT5ETGM2IMPDH2TAS1R3 | |
| Deoxy Adenosinediphosphate SCHEMBL5827743 | 0.93 | TGM2 (0.63) | POLBNT5ETGM2IMPDH2TAS1R3 | |
| SCHEMBL22352197 | 0.93 | NT5E (0.58) | POLBNT5ETGM2IMPDH2TAS1R3 | |
| SCHEMBL25712474 | 0.92 | TGM2 (0.62) | POLBNT5ETGM2IMPDH2FUT5 | |
| SCHEMBL7065119 | 0.92 | TGM2 (0.62) | POLBNT5ETGM2IMPDH2FUT5 | |
| SCHEMBL1913809 | 0.92 | TGM2 (0.62) | POLBNT5ETGM2IMPDH2FUT5 | |
| SCHEMBL22352187 | 0.91 | TGM2 (0.59) | POLBNT5ETGM2IMPDH2TAS1R3 | |
| SCHEMBL19147349 | 0.91 | NT5E (0.56) | POLBNT5ETGM2IMPDH2FUT5 | |
| SCHEMBL20698981 | 0.90 | NT5E (0.57) | POLBNT5ETGM2IMPDH2TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0048022-B1 | ENHANCER OF ANTI-TUMOR EFFECT | Yamasa Shoyu Kabushiki Kaisha (JP) | 1985-01-09 | — | — | EP | claimed |
| US-4432348-A | 3'-DEOXYGUANOSINE-5'-MONOPHOSPHATE OR 3'-DEOXYADENOSINE-5'-MONOPHOSPHATE | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1984-02-21 | — | — | US | claimed |
| EP-0048022-A2 | Enhancer of anti-tumor effect | Yamasa Shoyu Kabushiki Kaisha (JP) | 1982-03-24 | — | — | EP | claimed |
| JP-57067518-A | — | — | None | — | — | JP | disclosed |
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC | 2021-05-13 | — | — | US | disclosed |
| EP-1734046-B1 | Sulfopyranosylacylglycerol derivatives for use in combination with irradiation in an anti-tumor radiation treatment | TOYO SUISAN KAISHA (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-7074596-B2 | Synthesis and use of anti-reverse mRNA cap analogues | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2006-07-11 | — | — | US | disclosed |
| US-20030194759-A1 | Synthesis and use of anti-reverse mRBA cap analogues | DARZYNKIEWICZ, EDWARD (PL) | 2003-10-16 | — | — | US | disclosed |
| EP-0048022-B1 | ENHANCER OF ANTI-TUMOR EFFECT | Yamasa Shoyu Kabushiki Kaisha (JP) | 1985-01-09 | — | — | EP | disclosed |
| US-4432348-A | 3'-DEOXYGUANOSINE-5'-MONOPHOSPHATE OR 3'-DEOXYADENOSINE-5'-MONOPHOSPHATE | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1984-02-21 | — | — | US | disclosed |
| US-4432348-A | 3'-DEOXYGUANOSINE-5'-MONOPHOSPHATE OR 3'-DEOXYADENOSINE-5'-MONOPHOSPHATE | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1984-02-21 | — | — | US | disclosed |
| JP-S5767518-A | RADIOSENSITIZING AGENT OR AGENT FOR INCREASING EFFECT OF RADIOMIMETIC SUBSTANCE | YAMASA SHOYU CO LTD | 1982-04-24 | — | — | JP | disclosed |
| EP-0048022-A2 | Enhancer of anti-tumor effect | Yamasa Shoyu Kabushiki Kaisha (JP) | 1982-03-24 | — | — | EP | disclosed |
| EP-0048022-A2 | Enhancer of anti-tumor effect | Yamasa Shoyu Kabushiki Kaisha (JP) | 1982-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | STING1, CGAS, TLR7 | POLB 3219/4885NT5E 330/4885TGM2 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.